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Signalingf the EF-hand type, S100B, exerts both intracellular and extracellular functions.
Recent studies have provided more detailed information concerning the mechanism(s) of action of S100B as
an intracellular regulator and an extracellular signal. Indeed, intracellular S100B acts as a stimulator of cell
proliferation and migration and an inhibitor of apoptosis and differentiation, which might have important
implications during brain, cartilage and skeletal muscle development and repair, activation of astrocytes in
the course of brain damage and neurodegenerative processes, and of cardiomyocyte remodeling after
infarction, as well as in melanomagenesis and gliomagenesis. As an extracellular factor, S100B engages RAGE
(receptor for advanced glycation end products) in a variety of cell types with different outcomes (i.e.
beneﬁcial or detrimental, pro-proliferative or pro-differentiative) depending on the concentration attained
by the protein, the cell type and the microenvironment. Yet, RAGE might not be the sole S100B receptor, and
S100B's ability to engage RAGE might be regulated by its interaction with other extracellular factors. Future
studies using S100B transgenic and S100B null mice might shed more light on the functional role(s) of the
protein.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
S100B is a member of a family of Ca2+-binding proteins of the EF-
hand type comprising some 25members (see Refs. [1–5] for reviews).
S100B is expressed in varying abundance in a restricted number of cell
types such as astrocytes, maturing oligodendrocytes, kidney epithelial
cells, neural progenitor cells, pituicytes, ependymocytes, certain
neuronal populations, chondrocytes, adipocytes, melanocytes, Lan-
gerhans cells, dendritic cells, certain lymphocyte subpopulations,
skeletal myoﬁbers, myoblasts [1,3,6–12], and muscle satellite cells1.
Also, S100B expression is enhanced in several tumors arising from cell
types normally expressing the protein as well as in the aging brain and
in the brain of patients affected by Alzheimer's disease, chronic
epilepsy or HIV infection and other brain pathological conditions
[1,2,13–15]. The (level of) expression of S100B might strongly depend
on environmental factors. For example, S100B is undetectable in
normal cardiomyocytes, however it is induced in the myocardium
post-infarction concomitantly with the downregulation of the fetal
proteins, skeletal α-actin and β-myosin heavy chain [16] (Table 1).
These observations suggest that the S100B gene expression is under
complex transcriptional regulation. The S100B gene expression may
be constitutively repressed in all cell types by negative regulatory
elements, implying that the expression of S100B in a given cell type+39 075 585 7451.
submitted for publication.
ll rights reserved.requires induction of an appropriate factor that counters the action of
those elements [17]. Such a mechanism would allow a controlled
expression of S100B in deﬁnite cell types, in the same cell type
depending on the cell's functional states, or depending on the context.
This might also explainwhy S100B can be detected in several cell lines
derived from cell types that normally do not express the protein (for
example, see the case of microglia which do not express S100B in
tissue under normal and pathological conditions [18]; yet microglial
cell lines [19] and primary microglia [20] do express S100B). Besides
norepinephrine and phenylephrine in post-infarction cardiomyocytes
as noted above, the proinﬂammatory cytokine, interleukin (IL)-1β
[21], β-amyloid [22], antidepressants [23], brain-derived neuro-
trophic factor [24] and the neurotoxin 1-methyl-4-phenyl 1,2,3,6
tetrahydropyridine (MPTP) [25] upregulate S100B expression in
astrocytes (Table 1). In the latter case, the stimulatory effect of MPTP
on S100B expressionwas shown tobemodulated byendocannabinoids
via CB1 receptor activity [25]. Also, S100B is induced in enteric glia cells
by food gliadin in the duodenal mucosa of patients affected by celiac
disease [26] and in early-stage chondrocyte differentiation by sex-
determining region Y-type high mobility group box 5, 6 and 9 (the so-
called SOX trio) [27] (Table 1). On the other hand, epidermal growth
factor and the proinﬂammatory cytokine, interferon (IFN)-γ, have
been shown to downregulate S100B expression in astrocytes and
microglial cells [19,28,29] (Table 1).
S100B localizes to the cytoplasmwhere it is found in a soluble form
as well as associated with intracellular membranes, the centrosomes,
microtubules and type III intermediate ﬁlaments [3]. Like other
Table 1
Factors and/or conditions regulating S100B expression
Factors and/or conditions that increase
S100B expression levels
Factors and/or conditions that decrease
S100B expression levels
Norepinephrine and phenylephrine
(post-infarction cardiomyocytes) [16]
IFN-γ (microglial cell lines and astrocytes)
[19,28]
IL-1β (astrocytes) [21] Epidermal growth factor (astrocytes) [29]
β-amyloid [22] Dyslexia (astrocytes?) [33]
Antidepressants (astrocytes) [23] Differentiation of and/or acquisition of
quiescence (myoblasts)1Brain-derived neurotrophic factor
(astrocytes) [24]
MPTP (astrocytes) [18,25]
SOX trio (terminally differentiating
chondrocytes) [27]
Trisomy 21 [32]
Alzheimer's disease (astrocytes) [13]
Aging brain (astrocytes) [170]
Chronic epilepsy (astrocytes) [15]
HIV infection (astrocytes) [13–15]
Cell conﬂuency (astrocytes) [35]
Gliadin (enteric glia) [26]
Schizophrenia [191–193]
Cell types(s) and Refs. in parentheses.
Table 2
Factors and/or conditions regulating S100B secretion/release
Factors and/or conditions that increase
S100B secretion/release
Factors and/or conditions that decrease
S100B secretion/release
Growth phase (astrocytes) [35] High glucose (astrocytes) [63]
Catecholamines (adipocytes) [36] Inhibition of Src kinase (astrocytes) [61]
5-HT1A (astrocytes) [37] High glutamate (astrocytes) [64]
Lysophosphatidic acid [38] Cell conﬂuency (astrocytes) [35,42]
Glutamate (astrocytes) [39]
TNF-α (astrocytes) [40]
Metabolic stress (astrocytes) [41]
High cytosolic Ca2+ (astrocytes) [42]
Natural antioxidants (astrocytes) [43,44]
Branched-chain α-keto acids
(astrocytes) [45]
MPTP (astrocytes) [25]
Risperidone (astrocytes) [46]
Melanoma [47,48]
Acute phase of brain damage
(astrocytes) [50–52]
Intense physical exercise (adipocytes?,
skeletal myoﬁbers?) [54,55]
Dilated cardiomyopathy
(astrocytes?, cardiomyocytes?) [56]
Heart ischemia [57]
Non-brain traumas (adipocytes?,
skeletal myoﬁbers4) [58]
Cell types(s) and Refs. in parentheses.
1009R. Donato et al. / Biochimica et Biophysica Acta 1793 (2009) 1008–1022members of the family, S100B consists of a module of two Ca2+-
binding sites of the EF-hand (i.e., two helix–loop–helix motifs)
interconnected by a hinge region, and of a C-terminal extension
[1,2]. Also, like other members of the family (with exception of S100G
[CALB3, calbindin D9k]), S100B exists within cells as a homodimer in
which the two subunits are held together by non-covalent bonds and
are arranged in an anti-parallel fashion [30]. However, S100B also can
also exist as an S100B/S100A1 heterocomplex [1].
The human gene encoding S100B maps to chromosome 21q22.3
[31] with consequent overexpression of the protein in Down
syndrome [32]. Recently, S100B has been identiﬁed as a novel dyslexia
candidate gene along with three other genes (i.e., PCNT, DIP2A, and
PRMT2) mapping to chromosome region 21q22.3 [33].
Within cells S100B acts as a Ca2+ sensor protein. Upon Ca2+
binding, helix III of individual S100B monomers becomes more
perpendicular to helix IV, and this causes the hinge region to move
apart [30]. In consequence of these conformational changes a
number of hydrophobic residues in the hinge region, helices III and
IV and the C-terminal extension become exposed to the solvent.
These residues and, likely, residues in helix I of the opposite
monomer deﬁne a hydrophobic cleft through which dimeric S100B
binds to intracellular target proteins. However, other (as yet
undeﬁned) regions of the S100B dimer have been implicated in the
recognition of certain target proteins within cells, and S100B-target
protein interactions may not be Ca2+-dependent in some cases
[1,2,5]. In any case, S100B exerts its biological function by interacting
with other proteins thereby affecting their activities. Thus, S100B was
shown to take part in the regulation of cell proliferation, differentia-
tion and shape, Ca2+ homeostasis, protein phosphorylation, tran-
scription, the dynamics of microtubules and type III intermediate
ﬁlaments, enzyme activity and metabolism; its relatively high
abundance in the cell types where it is expressed and its cytoplasmic
localization make it possible that S100B can interact with a rather
large number of target proteins [1–3,5].
S100B also exerts extracellular effects. Indeed, S100B is actively
released by astrocytes [34,35], adipocytes [36] and, possibly, other cell
types. Also, S100B release by astrocytes can be augmented upon
stimulation with 5-HT1A [37], lysophosphatidic acid [38], glutamate
[39] and the proinﬂammatory cytokine, tumor necrosis factor (TNF)-α
[40], and during metabolic stress [41] (Table 2). Other stimulators of
S100B release from astrocytes include such diverse agents as relatively
high levels of cytosolic Ca2+ [42], natural anti-oxidants [43,44],
branched-chain α-keto acids [45], the neurotoxin MPTP [25], and theneuroleptic risperidone [46] (Table 2). Recent evidence suggests that
S100B is released by astrocytes via activation of metabotropic
glutamate receptor 3 in a neural- and synaptic-activity-dependent
manner [47]. In addition, S100B might leak from damaged cells
thereby accumulating in the extracellular space and/or entering the
bloodstream. For example, serum levels of S100B increase in patients
with melanoma [48–50], during the acute phase of brain damage [51–
54], following an intense physical exercise [55,56], and in the course of
dilated cardiomyopathy [57], heart ischemia [58] and non-brain
traumas [59]. Recently, S100B release has been suggested to occur in
isolated Schwann cells through a process that requires activation of
the cell surface receptor, RAGE (receptor for advanced glycation end
products, a member of the immunoglobulin superfamily [60,61]),
RAGE-dependent activation of the non-receptor Src tyrosine kinase,
Src-mediated phosphorylation of caveolin-1, phosphorylated caveo-
lin-1-dependent targeting of RAGE to Rab11-positive vesicles and
targeting of internalized RAGE to vesicles containing endogenous
S100B [62]. These results suggest that active S100B release might be
dependent on the presence and activation of RAGE on the cell surface,
and that S100B might stimulate its own release via RAGE engagement
(see below). These results raise questions about S100B secretion by
cells that do not express RAGE or express extremely low levels of the
receptor, such as all cell types after completion of development and in
the absence of pathological conditions, with the exception of certain
lung cells [60,61,63]. On the other hand, S100B secretion might be
reduced in e.g. primary astrocytes and Schwann cells treated with
high glucose [64], following inhibition of Src kinase [62], or upon
treatment with high doses of glutamate [65] as well as in conﬂuent
cells [35,42] (Table 2).
However, whatever the source of extracellular S100B and the
mechanism of its release, extracellular S100B might attain local
concentrations sufﬁcient to affect cellular activities by acting in a
paracrine, autocrine and endocrine manner. This latter issue calls for
the identiﬁcation of the cell surface molecule(s) transducing extra-
cellular S100B effects. While there is substantial evidence that RAGE
transduces extracellular effects of S100B on a variety of cell types
[66,67], RAGE might not be the sole S100B receptor (see below).
Concerning the S100B/RAGE interaction, there is evidence that S100B
binds to the RAGEV-domain [68], that the non-reducing and high Ca2+
conditions found extracellularly might favor the formation of S100B
Fig. 1. Schematic representation of proposed intracellular regulatory effects of S100B.
2 Brozzi, F., Arcuri, C., Giambanco, I., and Donato, R., submitted for publication.
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[68] or stabilization of preformed RAGE oligomers [70], an event
considered important for RAGE activation.
Several reviews have appeared describing intracellular and
extracellular regulatory effects of S100 proteins [1–5,71–85], to
which the reader can refer. However, the growing interest in S100B
and the increasing body of experimental data on intracellular and
extracellular S100B regulatory activities call for an updating of the
information concerning this particular S100 family member.
2. Intracellular regulatory activities of S100B
2.1. S100B/cytoskeleton interactions
As mentioned above, S100B is found co-localized with the centro-
somes, cytoplasmicmicrotubules, the center part ofmidbody in dividing
cells, and type III intermediate ﬁlaments. S100B has been shown to
modulate microtubule assembly and to cause microtubule disassembly
in aCa2+- andpH-dependentmannerand to increaseCa2+-sensitivity of
microtubules in situ [42,86,87]. Tubulin and themicrotubule-associated
τ protein have been reported to be S100B targets [88–90]. Also,
expression of S100B protein in E. coli causes a ﬁlamenting bacterial
phenotype characteristic of functional inhibition of FtsZ protein, the
prokaryotic ancestor of tubulin and amajor protein involved in bacterial
division, and leads to missed rounds of cell division [91]. Moreover,
disassembly of microtubules results in enhanced S100B release [42].
Further analyses are required to establish the functional relevance of
S100B/tubulin and/or microtubule interactions. The same applies to
S100B/intermediate ﬁlament interactions (Fig. 1).
S100B interacts with caldesmon in a Ca2+-dependent manner
inhibiting its phosphorylation and causing reversal of caldesmon-
dependent inhibition of actomyosin ATPase activity [92]. Caldesmon is
an actin-binding protein that is capable of stabilizing actin ﬁlaments
against actin-severing proteins, inhibiting actomyosin ATPase activity,
and inhibiting Arp2/3-mediated actin polymerization in vitro.
Caldesmon is a substrate of cdc2 kinase and ERK1/2 MAPK, and
phosphorylation by either of these kinases reverses the inhibitory
effects of caldesmon [93,94]. In principle S100B/caldesmon interac-
tions should result in stabilization of actomyosin (Fig. 1). However,
S100B is not found associated with F-actin or stress ﬁbers, and nofunctional correlates of S100B/caldesmon interactions in vivo have
been reported.
S100B was shown to interact in a Ca2+-dependent manner with
the small GTPase Rac1 and Cdc42 effector, IQGAP1, at the polarized
leading edge and areas of membrane rufﬂing in astrocytoma cell lines
[95]. Hence, S100B has been proposed to regulate IQGAP1 activity in
relation to cell migration. Rac1/Cdc42-regulated IQGAP1 cross-links
F-actin and participates in the organization of microtubules at the cell
cortical region, which leads to cell polarization andmigration [96–98].
In this context, S100B might act as an activator of IQGAP1 thereby
favoring cell migration (Fig. 1). Recent observations from our
laboratory show that S100B knockout in astrocyte cell lines by small
interference (si) RNA techniques results in disassembly of stress
ﬁbers, F-actin collapse onto plasma membranes, reduced migratory
capacity and acquisition of a stellate phenotype.2 These changes are
dependent on reduced activity of PI3-K, a kinase acting upstream of
the Akt (PKB)/GSK3β/Rac1 axis, which regulates the formation of
long cytoplasmic extensions, and the small GTPase RhoA/ROCK axis,
which governs stress ﬁber formation and cell locomotion [97,98].
Thus, S100B might regulate the supramolecular organization of F-
actin by acting upstream of the PI3-K/Akt/RhoA/ROCK axis thereby
favoring stress ﬁber formation and stimulating astrocyte migration
(Fig. 1), which might be important during brain development and in
the course of astrocytic neoplasias as well as in the course of brain
insult when astrocytes become activated and migrate to the site of
insult [99].
2.2. S100B in cell proliferation and survival
S100B has been long implicated in the regulation of cell
proliferation following the observation that its levels are elevated
in certain tumor cells and in astrogliosis [1,2] (Fig. 1). S100B was
reported to bind to and activate in a Ca2+-dependent manner Ndr
(nuclear Dbf2-related) [100], a serine/threonine protein kinase
belonging to subfamily of kinases implicated in the regulation of
cell division and morphology [101]. Ca2+/S100B was observed to
increase autophosphorylation on Ser-281 and Thr-444, resulting in
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by S100B is not associated with direct autoinhibition of the active
site, but rather involves a conformational change in the catalytic
domain triggered by Ca2+/S100B binding to the junction region
[103]. Yet, although S100B-dependent activation of Ndr in cell lines
has been documented [100], no evidence has been presented that
S100B-dependent activation of Ndr results in stimulation of cell
proliferation and/or changes in cell morphology.
S100B interacts in a Ca2+-dependent manner with the tumor
suppressor, p53, inhibiting its phosphorylation [104,105]. Phosphor-
ylation is a critical step of p53 activation [106–108] (Fig. 1). Also,
S100B downregulates p53 expression, and in turn, p53 downregulates
S100B expression in melanoma cells [109]. Upregulation of S100B in
melanoma is an established notion [1,2], and use of S100B immuno-
histochemistry and dosage of serum levels of S100B in patients with
melanoma is routinely performed for diagnostic and prognostic
purposes [48–50]. For the S100B/p53 interaction, it was found that
phosphorylation of speciﬁc serine and/or threonine residues reduces
the afﬁnity of the S100B-p53 interaction by as much as an order of
magnitude, and is important for protecting p53 from S100B-
dependent down-regulation [110]. However, there are conﬂicting
data about functional implications of S100B/p53 interactions
[109,111,112], and it is not known whether these interactions are
relevant for tumor progression in other malignant neoplasias and in
non-neoplastic cells. Work from our laboratory has shown that forced
expression of S100B in neuronal PC12 cells has no effects on p53 levels
or nuclear translocation, but it results in enhanced proliferation and
reduced differentiation and apoptosis via activation of a PI3-K/Akt/
p21WAF1/cdk4/Rb/E2F pathway in the absence of serum mitogens
[113] (Fig. 1).
Recently, we found that increasing S100B levels in myoblast cell
lines results in no effects on the proliferation rate of asynchronously
proliferating myoblasts; however, S100B-overexpressing myoblasts
are more resistant to basal and H2O2-induced apoptosis in an IKKβ/
NF-κB-mediated manner1 (Fig. 1). Thus, increasing S100B levels in
myoblasts results in augmented cell numbers in consequence of their
increased survival rate. In addition, non-fused myocytes (i.e.,
mitotically quiescent myoblasts that are found in mixed myoblast-
myotube cultures) transiently downregulate S100B expression,1
suggesting that downregulation of S100B might be required either
for acquisition of a quiescent status or for permitting myoblast
terminal differentiation. However, S100B-overexpressing myoblasts
are less prone to acquire mitotic quiescence and proliferate faster than
control cells upon re-exposure to serummitogens after quiescence (C.
Tubaro, C. Arcuri, I. Giambanco and R. Donato, unpublished data).
Proliferation of muscle satellite cells, the most relevant stem cell
population in adult skeletal muscle tissue, and their resistance to
death-inducing stimuli are critical for efﬁcient muscle regeneration as
well as for successful cell therapy of muscular dystrophy and wasting
[114–117]. Thus, S100B, which is expressed in muscle satellite cells,1
might contribute to muscle regeneration by reducing apoptosis and
stimulating the expansion of activated satellite cells. By contrast,
excess expression of S100B in satellite cells might be detrimental
because its mitogenic effect might interfere with the reconstitution of
the satellite cell reserve pool that normally occurs during the muscle
regenerative process and requires that a fraction of cells stop
proliferating and enter a quiescent state [114–117]. Future studies of
the dynamics of satellite cells in muscles of S100B null and transgenic
mice might help to verify the functional role(s) of S100B in these
particular cell types.
Also, work from our laboratory suggests that reducing S100B
expression in astrocyte cell lines results in a slight, though signiﬁcant
reduction of proliferation via reduced activity of the PI3-K/Akt
module and consistent reduction of cyclin D1, a protein important
for cell cycle progression2 (Fig. 1). However, these effects were
restricted to the ﬁrst two days of inhibition of S100B expression bysiRNA techniques, and no major effects of S100B levels at later time
points could be observed despite S100B levels were still signiﬁcantly
lower than in control cells.
Collectively, these data suggest that S100B might intervene in the
regulation of cell proliferation, survival and apoptosis by mechanisms
that vary depending on the cell type, the context and, probably, the
cell's normal or neoplastic condition. Further work is required to
deﬁnitely establish the role of S100B in cell proliferation and survival
in normal and neoplastic cells and to unravel the molecular
mechanisms by which the protein affects these cellular states.
Answering these questions also serves to establish whether elevation
of S100B levels in neoplastic cells is a consequence of tumorigenesis or
it is causally related to tumor progression.
2.3. S100B in cell differentiation
S100B appears to function as an inhibitor of cell differentiation. As
mentioned above, expression of S100B in PC12 neuronal cells results
in impaired NGF-induced differentiation via activation of a PI3-K/Akt/
p21WAF1/cdk4/Rb/E2F pathway [113] (Fig. 1). However, induction of
S100B expression in NGF-differentiated PC12 neuronal cells does not
reverse the differentiated phenotype [113], suggesting that the anti-
differentiative activity of S100B might be restricted to early develop-
mental stages and/or that other factors have to come into play for
S100B to concur to cell de-differentiation. Also, S100B, induced in
early-stage chondrocyte differentiation by the SOX trio, negatively
regulates chondrocyte terminal differentiation via an as yet undeter-
mined mechanism [27]. Interestingly, S100B expression in brain
astrocytic cells is developmentally regulated with different character-
istics depending on whether subventricular or cortical astrocytic cells
are considered, however [29]. These studies have established during
the time interval between post-natal days 2 and 8 ramiﬁed,
differentiating (i.e., glial ﬁbrillary acidic protein [GFAP] ﬁlament-
positive) astrocytes are substantially S100B-negative. This suggests
that during that time interval S100B might be downregulated, while
the protein becomes re-expressed during the ﬁnal phase(s) of
astrocytic differentiation. Moreover, S100B is expressed in radial
glial precursors [118], in the ventricular zone of embryonic mouse
cerebellum [119] and in progenitors of cerebellar granule cells [120],
the protein being expressed in these latter cells as long as they are
migrating. We have observed that reduction of S100B levels in
astrocyte cell lines results in reduced migration and acquisition of a
differentiated phenotype (i.e. stellation) due to reduced activity of the
PI3-K/RhoA/ROCK module, and increased activity of the GSK3β/Rac1
module2 (Fig. 1). Also, differentiation of primary astrocytes is
accompanied by a transient reduction of S100B expression, that is
restored at later developmental stages, i.e. in ramiﬁed astrocytes.2
These results are consistent with the possibility that repression of
S100B expression at certain phases of development of astrocytes and
certain neuronal populations might be functionally linked to their
differentiation. Thus, S100B might contribute to confer migratory
capacity on undifferentiated astrocytes and neuroblasts, and S100B
expression needs to be repressed for differentiation to take place. In
this context, S100B might act to avoid precocious differentiation
besides favoring cell migration.
S100B might modulate the differentiation of myoblasts, the
precursors of skeletal myoﬁbers. Indeed, overexpression of S100B in
myoblasts results in the blockade of the myogenic differentiation
program via IKKβ/NF-κB-mediated inhibition of expression of the
muscle-speciﬁc transcription factor, MyoD, and the MyoD-down-
stream effectors myogenin and p21WAF1, and conversely, reduction of
S100B expression in myoblasts by siRNA techniques results in reduced
NF-κB activity and enhanced myogenic differentiation1 (Fig. 1). It is
known that NF-κB is a negative regulator of myogenic differentiation
acting via inhibition of expression and/or reduction of stability of the
muscle-speciﬁc transcription factor, MyoD [121–123]. Interestingly,
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type myoblasts1 [11], which again suggests that S100B levels need to
decrease in certain cell types for their differentiation to occur, while
levels of S100B remain relatively high in fused myoblasts (myotubes).
While EFG has been proposed to reduce S100B expression in
developing astrocytes [29], the extracellular stimuli and intracellular
factors causing downregulation of S100B expression during cell
differentiation remain to be established. Also, as both mature
astrocytes and skeletal myoﬁbers express S100B [3], mechanisms
should exist that cause re-expression of the protein at later stages of
development. Overall, these observations suggest that functions of
S100B might be different in developing and mature cells and that
S100B might regulate different signaling pathways in different cell
types.
2.4. S100B and Ca2+ homeostasis
S100B null mice are viable and fertile and do not show any overt
phenotype [124] (but see below and the section Extracellular
regulatory activities of S100B, Effects of S100B on neurons). However,
astrocytes in cerebellar cultures derived from 6-days-old S100B null
mice exhibit enhanced Ca2+ transients in response to treatment with
KCl or caffeine, while granule neurons in the same cultures exhibit
normal Ca2+ transients in response to treatment with KCl, caffeine, or
N-methyl-D-aspartate [124] (Fig. 1). These results demonstrate a
speciﬁc decrease in Ca2+-handling capacity in astrocytes derived from
S100B null mice and suggest that S100B plays a role in the
maintenance of Ca2+ homeostasis in astrocytes. However, the
mechanism by which S100B accomplishes this function remains to
be elucidated.
The giant phosphoprotein AHNAK/desmoyokin, a desmosomal
plaque protein in epithelial tissues, is implicated in Ca2+ ﬂux
regulation. In epithelial cells, AHNAK is present mainly in the
cytoplasm when cells are kept in low Ca2+ medium but translocates
to the plasma membrane after an increase in extracellular Ca2+
concentration or protein kinase C (PKC) activation [125]. Also, AHNAK
has been found in cardiomyocytes associated with L-type Ca2+
channels. In these cells, AHNAK may play a role in cardiac Ca2+
signaling by modulating L-type Ca2+ channels in response to β-
adrenergic stimulation [126]. S100B has been shown to interact with
AHNAK in a Ca2+-dependent manner, and the S100B/AHNAK
interaction was proposed to participate in the S100B-mediated
regulation of cellular Ca2+ homeostasis [127] (Fig. 1). However,
deﬁnite evidence that this actually occurs in vivo is lacking.
As noted above, S100B is not expressed in cardiomyocytes in
normal conditions, but it becomes expressed under the action of
catecholamines in the cardiomyocytes surviving infarction and acts to
limit the hypertrophic response via inhibition of expression of α-actin
and β-myosin [16,128–130]. The activation of the S100B promoter was
shown to be mediated through the PKC signaling pathway; α1-
adrenergic stimulation induces the S100B gene after myocardial
infarction through the PKC signaling pathway and this induction is
modulated by transcription enhancer factor-1 (TEF-1) and related to
TEF-1 (RTEF-1) [129]. However, how S100B inhibits the expression of
α-actin and β-myosin remains to be elucidated. As the hypertrophic
response consequent to heart infarction is reminiscent of myoblast/
myotube hypertrophy in several aspects [131,132], the observation
that intracellular S100B has the potential to prevent precocious
myoblast differentiation via modulation of MyoD expression1 might
represent a possible link between catecholamine-dependent induc-
tion of S100B expression and reduced hypertrophic response in post-
infarction cardiomyocytes. Whether there is any relationship between
S100B-regulated AHNAK effects on Ca2+ ﬂuxes [126] and S100B-
dependent inhibition of post-infarction hypertrophic response in
cardiomyocytes also is currently unknown. Experimentally, S100B null
mice show enhanced hypertrophy of post-infarction cardiomyocytes,decreased apoptosis andmortality and a better preservation of cardiac
function in the 35-day period of observation after myocardial
infarction, compared with wild-type and S100B transgenic mice
[129]. Whether these effects are mechanistic related to altered
regulation of cytoplasmic Ca2+ in consequence of the absence of
expression of S100B remains to be established.
As astrocytic Ca2+ elevations play an important role in neurophy-
siology and especially in modulation of neuronal activity [133] it
would be interesting to investigate whether and to what extent the
defective Ca2+-handling capacity observed in astrocytes from S100B
null mice translates into alterations of neuronal activity.
2.5. S100B and enzyme activity regulation
No advancement of information concerning Ca2+/S100B-depen-
dent regulation of fructose-1,6-bisphosphate aldolase, phosphogluco-
mutase, twitchin kinase and membrane-bound guanylate cyclase has
been produced with respect to previous reviews [1–3] to which the
reader is invited to refer. See above for S100B/Ndr interactions and
potential regulatory effects of S100B on PI3-K/Akt, IKKβ and ERK1/2
(Fig. 1).
S100B has been shown to interact with the E3 ligase hdm2
implicated in p53 ubiquitination [110] (Fig.1). Although the functional
consequences of this interaction remain to be established, it has been
proposed that S100B might act in concert with hdm2 to modulate p53
levels and function.
Recent results suggest that S100B interacts with the third
cytoplasmic loop of the dopamine D2 receptor thereby causing
activation of ERK1/2 and inhibition of adenylyl cyclase activity via
an undetermined mechanism [134] (Fig. 1). However, S100B is
expressed sporadically and to a low level in striatal neurons [7,9],
and it is not known whether the S100B/D2 receptor interaction is
regulated by cytosolic Ca2+. Most importantly, D2 receptor is
expressed in astrocytes [135] and its activation has been shown to
result in release in neurotrophic factors [136,137]. Future studies
should analyze the functional relevance of S100B/D2 receptor
interactions in astrocytes.
3. Extracellular regulatory activities of S100B
3.1. Effects of S100B on neurons
Early studies have shown that S100B exerts neurotrophic effects
on neurons stimulating neurite outgrowth and regeneration in vitro
and in vivo [138–140], enhancing survival of neurons during
development [141–145] and after injury [146], and preventing
motor neuron degeneration in newborn rats after sciatic nerve
section [147]. S100B protects neurons towards toxic stimuli by
causing upregulation of the anti-apoptotic factor, Bcl-2 [148–150], via
engagement of RAGE and activation of a Ras/MEK/ERK1/2/NF-κB
pathway [149–152] (Fig. 2). Moreover, the intraventricular infusion
of S100B induces neurogenesis within the hippocampus, which has
been associated with an enhancement of cognitive functions
following experimental traumatic brain injury [153,154], and the
protein is released by in vitro trauma and reduces delayed neuronal
injury [20,155,156]. The protective effect of S100B towards neurons
may also be indirect, the protein stimulating uptake of the neurotoxic
glutamate by astrocytes [157], reducing neurotoxin-dependent
activation of microglia and astrocyte [158], and reducing neuronal
and glial cytotoxicity under hypothermic conditions [159]. The
neurite extension activity of S100B appears to be mediated by
RAGE-dependent activation of Cdc42-Rac1 [149] (Fig. 2). RAGE
engagement in neurons and myoblasts has been shown to result in
Cdc42-Rac1-dependent stimulation of neurite formation [160,161]
and differentiation and fusion into multinucleated myotubes [162],
respectively. Also, reduction of RAGE activity in acutely damaged
Fig. 2. Proposed model of effects of extracellular S100B on neurons. At low doses, S100B activates a RAGE-dependent production of moderate amounts of ROS and, probably,
activation of Src tyrosine kinasewith ensuing activation of a Ras-MEK-ERK1/2-NF-κB pathway leading to upregulation of expression the anti-apoptotic factor Bcl-2, and a Rac1-Cdc42
pathway leading to neurite extension. (B) At high doses, S100B activates a RAGE-dependent overproduction of ROS and excessive stimulation of the Ras-MEK-ERK1/2 pathway with
accompanying cytochrome-C release from mitochondria and activation of caspase-3, leading to neuronal apoptosis. The target(s) of ERK1/2 under these latter conditions have not
been elucidated. Schemes do not take into account multimerization of extracellular S100B and S100B-induced RAGE oligomerization and or RAGE oligomer stabilization. (1) S100B-
RAGE-ROS-dependent lipid peroxidation has been described in neural progenitors from Down syndrome brain only (Ref. [171]). One cannot exclude that this mechanism can operate
in any RAGE-expressing cell type exposed to high S100B concentration, however one should also take into account that responses of human Down syndrome neural progenitor cells
to S100B might be strongly dependent on the altered transcriptional regulation of a subset of genes throughout the entire genome in consequence of the increased levels of
expression of genes on chromosome 21.
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and functional recovery [163], supporting a role of RAGE in neurite
outgrowth. Interestingly, peripheral nerve crush results in an
increased expression of S100B in reactive Schwann cells in the
proximal and distal nerve stumps while nerve transection results in a
dramatic reduction of Schwann cell numbers and S100B content in
the distal, but not proximal nerve stump [164]. This suggests that the
S100B released by Schwann cells in acutely damaged peripheral
nerves might contribute to nerve regeneration likely via RAGE
engagement (also see Ref. [140]). By contrast, chronic activation of
RAGE is suggested to contribute signiﬁcantly to the impaired
peripheral nerve regeneration observed in diabetics [165]. Although
reduced release of S100B by Schwann cells occurs under high glucose
conditions [64], the role of the protein in chronic diabetic neuropathy
remains to be deﬁned.
Chronic administration of antidepressants has been reported to
result in proliferation of neuronal precursors in the adult brain [23].
Accordingly, antidepressants have been suggested to overcome stress-
induced atrophy and loss of hippocampal neurons and to contribute to
the therapeutic actions of antidepressant treatment. Antidepressants
have been also proposed to upregulate S100B expression in astrocytes
and RAGE expression in proliferating neuroblasts [23], suggesting the
possibility that these drugs might contribute to neuroblast prolifera-
tion via stimulation of S100B release from astrocytes and S100B-
induced RAGE signaling in neurons. However, direct evidence that
antidepressants stimulate S100B release from astrocytes is lacking. For
example, no information is available concerning effects of antide-
pressants on neuroblast proliferation in S100B null and transgenic
mice.
Collectively, these data suggest that S100B might exert protective,
neurotrophic effects during brain development, at early stages of brain
insult and in the course of regeneration of injured peripheral nerves.
Most importantly, neurotrophic effects are observed at nanomolar
doses of S100B, i.e. at the S100B concentrations thought to be presentin the brain extracellular space under normal conditions. By contrast,
at doses ≥500 nM the protein exerts toxic effects on neurons again in
a RAGE-mediated manner, via overproduction of reactive oxygen
species (ROS) and excess ROS-dependent activation of MEK/ERK1/2
[149] (Fig. 2), and enhances β-amyloid neurotoxicity [150]. Moreover,
at S100B doses N5 nM upregulates RAGE expression in neuronal cell
lines in a dose-dependent manner likely due to RAGE-mediated ROS
generation [150], in accordance with the notion that RAGE ligands can
upregulate RAGE expression and that ROS generation has an
important role in this effect [60,61]. These ﬁndings also suggest that
even at concentrations commonly thought to be protective towards
neurons, S100B might turn neurotoxic in the presence of excess ROS
generation. However, it has been reported that S100B at as high as
5 μM promotes neuronal survival via RAGE-dependent activation of a
PI3-K/Akt/NF-κB pathway [166], while others have shown that S100B
at doses ≥250 nM activates a RAGE/ROS/PI3-K/Akt/NADPH oxidase/
ROS pathway leading to lipid peroxidation and caspase-3 activation
that cause dorsal root ganglia neuron apoptosis [167] (Fig. 2) and still
others have found that S100Bmight cause neuronal cell death at doses
≥50 nM [25].
However, S100B transgenic mice show increased susceptibility to
perinatal hypoxia–ischemia [168], to intracerebral infusion of β-
amyloid [169] and to permanent middle cerebral artery occlusion
[170], suggesting the detrimental effect of constantly high levels of the
protein towards neurons. Signiﬁcantly, human Down syndrome
neural progenitor cell lines appear to have more the characteristics
of glial cell precursors than of neuronal precursors, and upon
switching them to EFG/FGF-deprived media they upregulate S100B
expression in contrast to age-matched cells from normal brain which
do not [171]. Administration of S100B to human Down syndrome
neural progenitor cells results in a dose- and time-dependent ROS
production and lipid peroxidation which lead to neuronal apoptosis
via RAGE-dependent activation of JAK/STAT, JNK, p38 MAPK and
caspase-3 [171] (Fig. 2). These effects begin to be seen at 50 nM S100B
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upregulates the expression of aquaporin-4, the major water channel
localized to astrocytic foot processes and expressed at ﬂuid-tissue
barriers throughout the brain and crucially involved in water
clearance and neuroprotection [172], in a RAGE- and ROS-dependent
manner in human Down syndrome neural progenitor cells, but not in
control cells [171]. The observation that an S100B-netralizing antibody
reduces basal ROS generation, lipid peroxidation and aquaporin-4
expression suggests that upregulation of S100B in human Down
syndrome neural progenitor cells results in enhanced release of the
protein which then acts in an autocrine manner [171]. Interestingly,
effects of administered S100B on ROS generation and lipid peroxida-
tion are enhanced in neuronal cell lines in which aquaporin-4 has
been downregulated [171], suggesting that S100B-induced upregula-
tion of aquaporin-4 expression is protective in nature. It should be
pointed out, however, that responses of human Down syndrome
neural progenitor cells to S100B might be strongly dependent on the
altered transcriptional regulation of a subset of genes throughout the
entire genome in consequence of the increased levels of expression of
genes on chromosome 21. Also, although experimental evidence is
lacking to our best knowledge, RAGE is expected to be upregulated in
Down syndrome neurons, which might contribute to the exquisite
sensitivity of human Down syndrome neural progenitor cells to
relatively low S100B concentrations. Collectively, these results suggest
that not only might S100B contribute to the neuropathological
changes typical of Down syndrome (and, likely, Alzheimer's disease);
S100B might also contribute to alter neurogenesis in Down syndrome,
reducing the number of neural progenitor cells.
Moreover, MPTP, a neurotoxin shown to produce neurological and
pathological changes comparable to those observed in Parkinson's
disease [173] has been reported to increase S100B expression in
astrocytes in vivo [18] and in vitro [25]. This latter study has also
shown that MPTP stimulates glial cell proliferation in coincidence
with increased levels of S100B (however, no causal relationship
between these two events has been described) and that the culture
medium of MPTP-treated cells reduces PC12 neuronal cell viability, an
effect that can be counteracted by an S100B-neutralizing antibody
[25]. Reduced PC12 neuronal cell viability under these conditions has
been thus attributed to enhanced release of S100B by astrocytes and
S100B-induced cell death.
Following the observation that levels of S100B are elevated in
several brain pathological conditions including Alzheimer's disease
and Down syndrome [13–15,32] and in the aging brain [174] (Table 1),
the idea has emerged that S100B might play a role in the
pathophysiology/pathogenesis of neurodegeneration and brain
inﬂammatory diseases, an idea corroborated by the astrocytosis and
axonal growth found in the hippocampus of S100B transgenic mice
[175], the neuronal cytoskeletal and behavioral signs of altered aging
processes detected in the brain of S100B transgenic mice [176], the
accelerated age-related deﬁcits including loss of dendritic and
synaptic markers in S100B transgenic mice [177], the increased
expression of apoptotic markers in the brain of S100B transgenic mice
[178], the losses in learning andmemory detected in S100B transgenic
mice [179], and the abovementioned increased susceptibility of S100B
transgenic mice to perinatal hypoxia–ischemia, intracerebral infusion
of β-amyloid and brain ischemic insult [168–170], and the neurotoxic
effects of S100B on human Down syndrome neural progenitor cells
[171]. Also, recent proteomic analyses of spinal cord injury classify
S100B as a proinﬂammatory cytokine [180]. However, as outlined
above, effects of S100B on neurons vary depending on the concentra-
tion and the context (i.e. the microenvironment), the protein exerting
protective effects on neurons at concentrations up to a few nanomolar
in vitro and turning detrimental at relatively high concentrations and/
or above a critical threshold of ROS generation in neurons and/or
nearby astrocytes and microglia [19,181,182]. Thus, it is possible that
baseline levels of extracellular S100B in the normal brain andincreases of S100B levels in the aging brain as well as at the very
initial stages of brain insults may exert beneﬁcial effects on neurons,
the protein promoting neuronal survival and neurite growth, as noted
above. However, the increases in baseline S100B levels seen with
aging and even more so in Down syndrome and Alzheimer's disease
may also increase susceptibility to pathologic processes characterized
by S100B overexpression [183] along with induction/upregulation of
RAGE expression. Signiﬁcantly, the neurite growth-promoting effects
of S100B have been implicated in the evolution of β-amyloid deposits
from benign, non-neuritic forms to the pathogenic neuritic forms that
are diagnostic of Alzheimer's disease [32,184], and there is also early
and life-long overexpression of S100B in Down syndrome. In addition,
recent data suggest that the oxidized/non-oxidized S100B ratio in the
brain extracellular space might contribute to the protein's trophic
effect via RAGE engagement in neurons or proinﬂammatory activity
via RAGE engagement in microglia [185]. Also, recent evidence
suggests that high levels of S100B cause GSK3β-dependent hyperpho-
sphorylation of τ protein via RAGE-dependent activation of JNK and
upregulation of Dickopff-1, a stimulator of GSK3β activity, in human
neural stem cells [186] (Fig. 2). It is known that hyperphosphorylated
τ protein is a major component of neuroﬁbrillary tangles, a hallmark
of Alzheimer's disease [187,188]. Together with the observation that
S100B increases levels of β-amyloid precursor protein in neuronal
cultures [189] and that elevation of levels of S100B in the brain of a
mouse model of Alzheimer's disease precedes the appearance of
neuritic β-amyloid plaques [190], these ﬁndings might represent a
mechanistic link between overexpression of S100B in Alzheimer's
disease and Down syndrome brain and the elevated expression of
S100B in reactive astrocytes in proximity of neuroﬁbrillary tangles
[32].
Moreover, although experimental evidence suggests that S100B
might act as a serotonergic growth factor [191–194], genetic analyses
indicate that S100B null mice show normal development of
serotonergic neurons [195]. While compensatory mechanisms might
come into play in these mice, these authors however reported that
S100B null mice exhibit enhanced spatial and fear memories as well as
enhanced long-term potentiation (LTP) in the hippocampal CA1
region, and perfusion of hippocampal slices with S100B reverses the
levels of LTP to those of the wild-type slices [196]. This suggests that
extracellular S100B might play a role as a regulator of synaptic
plasticity, although the molecular mechanism underlying this activity
remains to be elucidated. S100B has long been implicated in learning
and memory processes (for review see Refs. [1,177,197]), and it has
been reported to affect neuronal electrical discharge activity by
modulation of potassium currents at subnanomolar concentrations
[198] (also see S100B and Ca2+ homeostasis above).
However, recent evidence shows that S100B release is increased in
a mouse model of epilepsy, that the amplitude of hippocampal kainic
acid-induced gamma oscillations is signiﬁcantly reduced in S100B null
mice compared with wild-type mice, and that released S100B
enhances hippocampal kainic acid-induced gamma oscillations, an
event that is abrogated by the local infusion of either an S100B
neutralizing or a RAGE neutralizing antibody [47]. As the enhanced
S100B release that occurs following kainic acid treatment was shown
to be dependent on the activation of astrocytic metabotropic
glutamate receptor 3 via a neural and synaptic activity [47], these
results have been proposed to indicate that astrocytes release S100B
during epileptic seizures under the action of neuronal glutamate, in
accordance with the increased levels of brain S100B detected in
epileptic patients [15]. It seems that a 4-fold (i.e. from 2.5 nM to
10 nM) increase in extracellular S100B concentration as measured in
kainic acid-treated hippocampal slices, compared with control slices,
and S100B-activated RAGE signaling make neurons more sensitive to
the epileptogenic activity of kainic acid [47] via a mechanism that
remains to be elucidated. How this can be reconciled with the
neurotrophic, i.e. anti-apoptotic and neurite growth-promoting
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neuronal membrane iperpolarization discussed above remains to be
elucidated. It is possible that S100B iperpolarizes inhibitory inter-
neurons in the hippocampus thereby causing dysinhibition of
pyramidal neurons and enhancing their sensitivity to kainic acid.
Overall, the cellular localization of RAGE in the model system used in
Ref. [47] remains to be established.
On the other hand, a positive correlation has been found between
serum and cerebrospinal levels of S100B and schizophrenia [199–201]
(Table 1). The functional relevance of elevated levels of S100B in the
pathophysiology of schizophrenia is still elusive, and information is
lacking about the temporal and spatial expression of RAGE in the brain
of schizophrenics. However, high S100B levels in schizophrenia seem
not to represent a generic index of glial and/or neuronal damage;
rather they reﬂect increased release of the protein [202]; epidemio-
logical studies have indicated that the risk of developing neuropsy-
chiatric disorders in offspring is enhanced by prenatal maternal
infection [203]; and genetically mediated brain microvascular
inﬂammatory disease has been proposed to contribute substantially
to schizophrenia [204]. Thus, in principle high S100B levels might play
a role in the pathophysiology of schizophrenia via RAGE engagement
given the documented role of RAGE engagement in inﬂammatory
processes [60,61,205] (also see below). Moreover, as noted above
S100B reduces LTP, and LTP is depressed in schizophrenics [206].
It should be pointed out, however, that we ignore the exact
levels of extracellular S100B in the brain under normal and
pathological conditions (but see Ref. [47]), thus results obtained
using cell models might not offer a realistic representation of events
in which S100B is involved. In addition (and as in the case of any
other extracellular factor affecting the activity of target cells), S100B
effects on target cells might be modiﬁed by the myriad of distinct
stimuli that likely modify the action of S100B in vivo. That said, the
sometime opposing effects exerted by S100B on responsive cells at
subnanomolar–nanomolar and submicromolar–micromolar concen-
trations in vitro together with the results of analyses of brain S100B
levels in Down syndrome and Alzheimer's disease point to a dualFig. 3. Proposed model of effects of S100B on astrocytes and microglia. (Left) RAGE engagem
expression. (Right) At high doses S100B synergizes with IFN-γ to upregulate iNOS expression
with IFN-γ is not known (?). At high doses S100B also causes a RAGE-dependent (over)prod
Ras-Rac1-Cdc42-MKK4/7-JNK-AP-1 pathway and a Ras-Rac1-NF-κB pathway with ensuing
NF-κB pathway and a Ras-Rac1-Cdc42-MKK6-p38 MAPK-NF-κB pathway might contribut
multimerization of extracellular S100B and S100B-induced RAGE oligomerization and or RAregulatory role of the extracellular protein, that can be well
expressed by the use of terms such as low and high (i.e., 2 to 3
orders of magnitude larger) doses.
3.2. Effects of S100B on astrocytes
S100B affects astrocytes in an autocrine manner. Early studies
have shown that S100B stimulates astrocyte cell line proliferation at
low doses [207], and inducible nitric oxide (iNOS) synthase activity
and mRNA levels in rat cortical astrocytes at higher concentrations
[208] via activation of NF-κB [209] (Fig. 3). The NO generated by high
S100B causes astrocyte apoptosis [210] as well as apoptosis of co-
cultured neurons [182]. Also, (high) S100B upregulates IL-1β
expression in astrocytes and enhances β-amyloid-induced glial
activation [211], and stimulates the release of IL-6 and TNF-α from
astrocytes at doses ≥25 nM [212] (Fig. 3). Thus, S100B can activate
astrocytes, i.e. it may take part in the process that switches astrocytes
from trophic cells to cells that participate in the brain inﬂammatory
response. It cannot be excluded, however, that S100B-induced
apoptosis of astrocytes might contribute to reduce the number of
activated astrocytes during the course of brain inﬂammatory
processes. From this standpoint, S100B might play a role in the
process of resolution of inﬂammation. Effects of S100B on astrocytes
appear to be dependent on engagement of RAGE [212]. On the other
hand, low (i.e., subnanomolar to nanomolar) doses of S100B have
been shown to counter the activating effects of the neurotoxin,
trimethyltin, on astrocytes [158].
S100B has been also shown to activate enteric glia cells in the
duodenal mucosa of patients with celiac disease but not normal
mucosa, upregulating iNOS expression and stimulating NO production
and lipid peroxidation in a p38 MAPK-NF-κB-dependent manner and
in a dose-dependent fashion with maximum effect in the micromolar
range [26]. These results raise the possibility that gliadin-induced
upregulation of S100B expression in and release from enteroglial cells
might play an important role in the pathogenesis/pathophysiology of
celiac disease.ent by S100B results in NF-κB-dependent upregulation of IL-1β, IL-6, TNF-α and iNOS
and NO production in microglia. The molecular mechanism by which S100B synergizes
uction of ROS likely via activation of the NADPH oxidase complex. In turn, ROS activate a
upregulation of expression of COX-2, IL-1β and TNF-α expression. A Ras-MEK-ERK1/2-
e to upregulation of IL-1β and TNF-α expression. Schemes do not take into account
GE oligomer stabilization.
Fig. 4. Proposed model of effects of S100B on monocytes/macrophages. At high doses
S100B cause a RAGE-dependent (over)production of ROS via activation of the NADPH
oxidase complex. In turn, ROS activate Src tyrosine kinase which recruits a Ras-MEK-
ERK1/2-NF-κB pathway and a Rac1-Cdc42-MKK6-p38 MAPK-NF-κB pathway with
ensuing upregulation of IL-1β, TNF-α, COX-2 and iNOS expression. Schemes do not take
into account multimerization of extracellular S100B and S100B-induced RAGE
oligomerization and/or RAGE oligomer stabilization.
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At subnanomolar to nanomolar doses S100B blocks activating
effects of the neurotoxin, trimethyltin, on microglia [158], the brain
resident macrophages. The receptor transducing these S100B effects is
not known. However, these analyses were conducted on primary
microglia [158] and it is known that RAGE is expressed in nervous cells
during brain development [213,214]. Thus, at physiological levels
S100B might counter neurotoxin effects on microglia via RAGE
engagement. RAGE is also expressed in mature brain cells under
normal conditions, albeit at a low level, and its expression increases in
several neurodegenerative processes [215–218]. Thus, S100B might
counter effects of neurotoxins in the mature brain at the initial phases
of brain insults.
By contrast, at high doses S100B activates microglia, which are
known to participate in the brain inﬂammatory response. Indeed,
S100B synergizes with bacterial endotoxin and IFN-γ, to upregulate
iNOS expression in and NO release from microglia [19,181] (Fig. 3),
suggesting that on accumulation in the brain extracellular space the
protein might participate in the brain inﬂammatory response in case
of insults. S100B's ability to stimulate NO release by microglia is not
dependent on RAGE transducing activity, though dependent on the
density of RAGE molecules at the microglial surface, and requires the
production of ROS and activation the MKK6-p38 mitogen-activated
protein kinase (p38 MAPK) [219]. Because in the absence of co-factors
the amount of S100B-induced NO release by microglia is marginal
[19], one might speculate that in the course of brain inﬂammatory
processes the RAGE extracellular domain might anchor and recruit
S100B to the microglial surface thereby permitting the protein to
potentiate bacterial endotoxin and IFN-γ ability to stimulate NO
release.
By contrast, S100B upregulates the expression of the pro-
inﬂammatory enzyme, cyclo-oxygenase (COX)-2, in microglia in the
absence of co-factors, and this effect requires RAGE's transducing
activity [220] (Fig. 3). The importance of COX-2 expression and
activity is highlighted by its ability to convert arachidonic acid into
prostaglandins, that are inﬂammation mediators; tight regulation of
COX-2 expression in several cell types including microglia is a key
feature controlling eicosanoid production in inﬂammatory syndromes
[221]. RAGE engagement by S100B in microglia results in the
activation of a Cdc42/Rac1-JNK and a Ras-Rac1-NF-κB pathway each
of which is necessary and sufﬁcient for S100B/RAGE to upregulate the
enzyme [220]. Speciﬁcally, S100B/RAGE-dependent upregulation of
COX-2 expression in microglia requires the concurrent activation of
the Rac1-NF-κB module and the Rac1-JNK-AP-1 module [222]. These
effects are seen at relatively high S100B concentrations, suggesting
that S100B has to accumulate in the brain extracellular space for it to
be able to induce COX-2 expression in microglia. However, at doses
that do not result in COX-2 upregulation S100B upregulates the
enzyme in microglia in the presence of concentrations of either IL-1β
or TNF-α that do not affect COX-2 expression per se [222], implying
that S100B might switch from protective to detrimental at the very
beginning of the brain inﬂammatory response.
S100B also stimulates the production of IL-1β, via activation of
ERK1/2, p38 MAPK and JNK in primary microglia [223] (Fig. 3). These
effects are likewise dependent on RAGE engagement [222]. Moreover,
S100B stimulates TNF-α production inmicroglia in a RAGE-dependent
manner [222]. S100B/RAGE-dependent upregulation of IL-1β and
TNF-α also occurs via the concurrent activation of the Rac1-NF-κB
module and the Rac1-JNK-AP-1 module and the possible, though not
critical contribution of the ERK1/2-NF-κB module and p38 MAPK-NF-
κB module [222] (Fig. 3). In this context, it is noteworthy that TNF-α
stimulates S100B release from astrocytes [40], suggesting the
possibility that in case of brain insult TNF-α might concur to elevate
the extracellular concentration of S100B thereby favoring the
activating effects of S100B on microglia. Collectively, these datasuggest that S100B might have a role in the pathogenesis of brain
disorders associated with Alzheimer's disease, Down syndrome and
other neurodegenerative processes, i.e. conditions in which microglia
activation has been documented, as well as in neuroinﬂammation
consequent to autoimmune diseases, infections and traumas.
3.4. Effects of S100B on monocytes/macrophages, T-lymphocytes,
endothelial cells, vascular smooth muscle cell, retinal pigment
epithelial cells, neutrophils and lens epithelial cells
S100B engages RAGE in the human monocytes cell line, THP-1, and
human peripheral blood monocytes thereby upregulating COX-2
expression and increasing production of prostaglandins [224]. These
effects require RAGE-dependent generation of ROS and activation of
PKC, ERK1/2, p38MAPK and NF-κB (Fig. 4). Moreover, S100B increases
adherence of monocytes to vascular smooth muscle cells (VSMCs)
again in a RAGE-PKC-p38 MAPK-ERK1/2-NF-κB-dependent manner
[224]. S100B also increases IFN-γ-inducible protein (IP)-10 mRNA and
protein levels in THP-1 monocytes as well as peripheral blood
monocytes via augmentation of IP-10 mRNA half-life and stability,
and TNF-α release from peripheral blood monocytes, in a RAGE-
dependent manner [225,226]. Moreover, S100B primes O2− generation
in monocytes via RAGE engagement [227] and stimulates NO
production in macrophages via p38 MAPK activation [228]. In
addition, at relatively high concentrations S100B engages RAGE in
neutrophil-like HL-60 cells and induces the translocation of p47phox,
a key component of the NADPH oxidase, to the cell membrane
compartment at least in part via ERK1/2, leading to superoxide
generation, and this effect is enhanced in high glucose conditions
[229] (Fig. 4). Also, S100B enhances neutrophil sensitivity to N-
formyl-methionyl-leucyl-phenylalanine, a chemoattractant molecule
3 F. Riuzzi, G. Sorci and R. Donato, manuscript in preparation.
4 F. Riuzzi, G. Sorci and R. Donato, manuscript in preparation.
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line of defense against bacterial invasion by engaging RAGE in
neutrophils besides macrophages and microglia.
Collectively, these results suggest that by binding to and activating
RAGE S100B can induce inﬂammatory gene expression and facilitate
oxidative burst in monocytes/macrophages/microglia and neutro-
phils. As discussed elsewhere [67], it should be noted that serum
S100B might hardly attain the high concentrations shown to be
required for inducing inﬂammatory gene expression in circulating
monocytes. Yet, locally accumulated S100B might activate tissue
macrophages. For example, the large amount of S100B released from
necrotic melanoma cells [230] might engage RAGE in macrophages
thereby stimulating a local inﬂammatory response and release of TNF-
α, a cytokine that is upregulated in tumor states and is responsible for
several systemic effects in the course of neoplasias [231–233]. These
ﬁndings underline the importance of S100B/RAGE interactions in
macrophages, which might be important in relation to those chronic
inﬂammatory states that accompany (and/or represent a relevant
component of) several pathological conditions, including chronic
inﬂammatory diseases, diabetes and tumors as well as in relation to
acute inﬂammatory states.
S100B has been shown to chemoattract RAGE-expressing ence-
phalitogenic CD4+ Th1 T-cells in a model of experimental auto-
immune encephalomyelitis (whichmimicsmultiple sclerosis) thereby
promoting T-cell inﬁltration of the central nervous system [234]. Thus,
S100B might play an important role in the pathogenesis/pathophy-
siology of multiple sclerosis both by chemoattracting RAGE+-CD4+ T-
cells and by activating astrocytes and microglia via RAGE engagement.
Consistently, others have found that the expression of S100B is
signiﬁcantly reduced in Borna disease virus (BDV)-infected brains
despite severe astrocytosis with increased GFAP immunoreactivity
and that BDV infection may impair astrocyte functions via a down-
regulation of S100B expression, leading to the maintenance of a
persistent infection [235].
S100B engages RAGE in endothelial cells thereby activating NF-κB
transcriptional activity [66], increasing expression of vascular cell
adhesion molecule-1 [227] and inducing monocyte chemoattractant
protein-1 (MCP-1) and RAGE transcripts [236] and eliminating
sodium nitroprusside-potentiated vasodilatation in response to ACh
in endothelial dysfunction in type II diabetic (Leprdb) mice [237]. Also,
S100B enhances the interaction of RAGE with the leukocyte β2-
integrin Mac-1 thus potentially increasing leukocyte adhesion to
endothelial cells [238].
RAGE engagement in VSMCs results in increased ROS generation
via stimulation of NADPH oxidase, and janus kinase (JAK) 2 tyrosine
phosphorylation via activation of phospholipase D2, these effects
being enhanced in the presence of high glucose concentrations or
angiotensin II [239]. These effects translate into VSMC proliferation.
Moreover, RAGE engagement by S100B in VSMCs results in recruit-
ment of the non-receptor Src tyrosine kinase and PKC and phosphor-
ylation of caveolin-1, a component of caveolae, and that the effects of
S100B/RAGE on VSMCs [239] plus stimulation of VSMCmigration and
release of IL-6, require p38MAPK, ERK1/2, NF-κB and STAT3 activities,
and ROS production [240]. Notably, the integrity of caveolae (i.e.,
stable membrane domains that are kept in place by the actin
cytoskeleton and act as multifunctional organelles [241,242]) is
required for assembly of RAGE with Src tyrosine kinase and for
S100B-stimulated RAGE signaling via Src tyrosine kinase in VSMCs
[240]. For a schematic representation of S100B effects on VSMCs see
Fig. 3 in Ref. [66].
Immobilized (i.e., oligomeric) S100B increases vascular endothelial
growth factor (VEGF) secretion by retinal pigment epithelial cells in
vitro in a RAGE/NF-κB-dependent manner [69], thus potentially
inciting or propagating neovascular macular disease.
S100B also upregulates RAGE and transforming growth factor-β in
human lens epithelial cells as well as nuclear accumulation ofphosphorylated Smad2/3 [243], which might have implications in
the context of eye complications in diabetics.
In conclusion, the S100B/RAGE interaction might be important for
macrophage/microglia and neutrophil activation, S100B having
properties of the so-called defensins or alarmins. Also, the S100B/
RAGE interaction might play a role in embryonic and reactive
angiogenesis and in the pathophysiology of microcirculation defects,
and in the course of several pathological conditions including
diabetes, brain insults, infections, inﬂammatory diseases, and cardiac
infarction (in the latter case because of the α1-adrenergic-induced
expression of S100B in surviving cardiomyocytes and leakage of S100B
from damaged cardiomyocytes [129]). Moreover, while the number of
cell types capable of expressing and releasing S100B under normal
and pathological conditions is relatively small, in organs/tissues
endowed with S100B-positive cells the release of the protein
consequent to constitutive or stimulated secretion, leakage from
damaged cells or cell necrosis might result in S100B-mediated
activation of RAGE in endothelial cells and VSMCs and in VEGF-
releasing cells.
3.5. Effects of S100B on myoblasts/muscle satellite cells
S100B exerts regulatory effects on myoblast proliferation and
differentiation by activating of the mitogenic Ras/MEK/ERK1/2
module and inhibiting the promyogenic MKK6/p38 MAPK module
in a receptor-mediated manner with half-maximum effect at
∼50 pM and maximum effect at ∼100 pM [244,245]. It is known
that for myoblasts to differentiate into fusion-competent myocytes,
they have to stop proliferating [114]. S100B also promotes myoblast
survival by activating the Ras/MEK/ERK1/2/NF-κB module [245]. In
light of the anti-myogenic activity of NF-κB [121–123], S100B-
dependent activation of this transcription factor might contribute to
the overall anti-differentiative activity of S100B on myoblasts.
However, S100B's anti-myogenic effects appear to be exerted on
high-density myoblasts only. Current work suggests, in fact, that
S100B inhibits high-density myoblast differentiation by activating
bFGF receptor-1 (FGFR1).3 By contrast, in case of low-density
myoblasts and as long as myoblasts are present at a low density,
S100B stimulates proliferation and activates the myogenic program
via RAGE-dependent stimulation of the mitogenic MEK/ERK1/2 and
the promyogenic p38 MAPK, respectively, with no apparent role for
FGFR1.3 However, S100B does not bind FGFR1 and no S100B-
dependent activation of FGFR1 occurs in the absence of bFGF.3
Indeed, S100B interacts with bFGF although at relatively high
S100B/bFGF molar ratios and likely potentiates bFGF-dependent
FGFR1 activation.3 Thus, a quaternary RAGE-S100B-bFGF-FGFR1
complex, in which an S100B/bFGF complex cross-links RAGE to
FGFR1, forms in high-density myoblasts, and under these conditions
RAGE is prevented from activating p38 MAPK, while in low-density
myoblasts S100B can bind to and activate RAGE but not FGFR1 likely
because of the high abundance of the bFGF released and lack of
complex formation between S100B and bFGF under these condi-
tions.3 Myoblast density and the local concentration of bFGF thus
appear to dictate the overall effect of S100B on myoblast
differentiation. Also, the local injection of S100B into mouse muscles
results in an enhancement of the satellite cell number and satellite
cell proliferation, an effect not occurring in RAGE null mice.4 Thus, it
appears that the principal effect of S100B on myoblasts is that of
stimulating their proliferation. Moreover, extracellular S100B acti-
vates quiescent myoblasts in vitro and stimulates their migration.4
As mentioned in Introduction, serum levels of S100B increase
following an intense physical exercise [55,56] during which the
protein might be released from adipocytes under the action of
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known that an intense physical exercise causes skeletal myoﬁber
damage that is followed by myoﬁber regeneration in a relatively
short time under normal conditions via activation of muscle satellite
cells, their emigration and proliferation, and their eventual
differentiation into fusion-competent myocytes [114]. It is tempting
to speculate that the S100B released locally by damaged myoﬁbers
might contribute to the process of muscle regeneration by virtue of
its ability to activate and expand satellite cells. However, as with
neuronal and astrocytic cell lines [149,150,210,246], at high doses
S100B causes myoblast apoptosis in vitro via excess generation of
ROS [247].
3.6. Structural requirements for S100B/RAGE interaction
Although RAGE engagement may not be the sole means whereby
S100B brings about its effects on target cells, RAGE deﬁnitely is an
important S100B's receptor. Recent work has shown that S100B
tetramers and, likely, higher-order oligomers bind to the RAGE
immunoglobulin V extracellular domain and cause RAGE oligomer-
ization [67] and/or stabilization of preformed RAGE oligomers [69].
Notably, RAGE oligomerization is required for S100A12, S100A6,
AGE-modiﬁed proteins and, likely, other S100 proteins to activate
RAGE [66]. Also importantly, differences have been reported
concerning the structural motifs of RAGE extracellular domain
engaged by the various RAGE ligands, possibly explaining the
differential effects exerted by the different RAGE ligands in different
cell types.
3.7. Concluding remarks
Increasing evidence indicates that S100B exerts functional roles by
acting as an intracellular regulator and an extracellular signal. Within
cells, S100B acts as a stimulator of proliferation and migration and an
inhibitor of apoptosis and differentiation. These S100B effects might
be important during brain, cartilage and skeletal muscle development,
activation of astrocytes in the course of brain insults and neurode-
generative processes and satellite cells in the course of muscle
regeneration, and of cardiomyocyte remodeling after infarction, as
well as in gliomagenesis and melanomagenesis.
S100B is secreted by several cell types and released by damaged
cells. Once released, S100B exerts regulatory effects on a relatively
larger number of cell types in an autocrine, paracrine and, possibly,
endocrine manner. Thus, S100B also is an extracellular signal. RAGE
has been identiﬁed as an S100B receptor, transducing S100B effects
on a variety of cell types with different outcomes (i.e. beneﬁcial or
detrimental, pro-proliferative or pro-differentiative) depending on
the concentration attained by the protein and the cell type. The
physicochemical state, i.e. dimeric, tetrameric, octameric or oligo-
meric, of S100B appears to have an important role in the intensity
(and duration of) activation of RAGE and, hence, in the ﬁnal effects
of RAGE-mediated S100B actions. Environmental parameters such
as the Ca2+ and/or ROS concentration and the S100B clearance
rate also might inﬂuence S100B/RAGE ﬁnal effects. However, RAGE
might not be the sole S100B receptor, and not always S100B/RAGE
interactions might be physiologically/pathophysiologically relevant.
In fact, S100B is being used as a RAGE agonist in several
experimental settings that might not correspond to conditions
where S100B is really present or it is present at the concentrations
tested.
In face of the plethora of data on intracellular and extracellular
regulatory effects of S100B, few data are available by genetic
approaches. Availability of S100B null and transgenic mice, RAGE
null mice and, hopefully, double S100B/RAGE null mice might help to
distinguish between functionally relevant effects of S100B and
irrelevant results.Acknowledgements
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